Il pembrolizumab nel trattamento del melanoma: Aggiornamenti e prospettive

Translated title of the contribution: Pembrolizumab for the treatment of melanoma: Updates and perspectives

Research output: Contribution to journalReview articlepeer-review


Checkpoint inhibitors immunotherapy was a breakthrough in anti-Tumor treatments. Anti-PD-1 monoclonal antibodies are now a standard of treatment for advanced melanoma patients, with a 3-year overall survival of over 50% and a low rate (<20%) of severe toxicities in the phase 3 studies. The aim of this review was to report the most important updates on anti-PD-1 drug pembrolizumab from ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) 2017 Annual Meetings.

Translated title of the contributionPembrolizumab for the treatment of melanoma: Updates and perspectives
Original languageItalian
Pages (from-to)528-531
Number of pages4
JournalRecenti Progressi in Medicina
Issue number12
Publication statusPublished - Dec 1 2017

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pembrolizumab for the treatment of melanoma: Updates and perspectives'. Together they form a unique fingerprint.

Cite this